» Articles » PMID: 38151294

Impact of Mutations in Subunit Genes of the Mammalian SWI/SNF Complex on Immunological Tumor Microenvironment

Abstract

Background/aim: Recently, inactivating somatic mutations of SWI/SNF chromatin-remodeling genes in cancers have been reported. However, few studies have been performed regarding the immunological analysis of the tumor microenvironment (TME) in chromatin remodeling complex gene-mutated tumors. In the present study, we identified cancer patients harboring various mammalian SWI/SNF complex mutations and investigated the immunological features in those mutated cancers.

Patients And Methods: Cancer patients harboring any type of chromatin remodeling complex gene mutation were selected and clinicopathological features were compared between chromatin remodeling complex gene expression-low and expression-high groups. Specifically, expression levels of immune response-associated genes and cancer-associated genes were compared between the SMARCA4 expression-low and expression-high groups using volcano plot analysis.

Results: Among cancers harboring PBRM1, SAMRACA4 and ARID2 gene mutations, T-cell marker and mature B-cell marker genes were up-regulated in the tumor. Specifically, T-cell effector genes (CD8B, CD40LG), central memory marker genes (CD27, CCR7) and mature B-cell marker genes (CD20, CD38, CD79 and IRF4) were up-regulated, and cancer-associated genes including MYB, MYC and AURKB genes were down-regulated in the SMARCA4 expression-low group. Remarkably, heatmap of gene expression and immunohistochemistry (IHC) data demonstrated that the tertiary lymphoid structure (TLS) gene signature of mature B cells was up-regulated in SMACA4 gene-mutated stomach cancers.

Conclusion: These results suggest that immune tumor microenvironment status, such as mature B cell recruitment featuring the TLS gene signature and immune activation mediated by cancer signal down-regulation, might contribute to the classification of SMARCA4 gene-mutated tumors as immune checkpoint blockade therapy-sensitive target tumors.

Citing Articles

Treatment of Thoracic SMARCA4-Deficient Undifferentiated Tumors: Where We Are and Where We Will Go.

Longo V, Catino A, Montrone M, Montagna E, Pesola F, Marech I Int J Mol Sci. 2024; 25(6).

PMID: 38542211 PMC: 10970296. DOI: 10.3390/ijms25063237.

References
1.
Jelinic P, Mueller J, Olvera N, Dao F, Scott S, Shah R . Recurrent SMARCA4 mutations in small cell carcinoma of the ovary. Nat Genet. 2014; 46(5):424-6. PMC: 5699446. DOI: 10.1038/ng.2922. View

2.
Jiang J, Wang J, Yue M, Cai X, Wang T, Wu C . Direct Phosphorylation and Stabilization of MYC by Aurora B Kinase Promote T-cell Leukemogenesis. Cancer Cell. 2020; 37(2):200-215.e5. PMC: 7321798. DOI: 10.1016/j.ccell.2020.01.001. View

3.
Toumpeki C, Liberis A, Tsirkas I, Tsirka T, Kalagasidou S, Inagamova L . The Role of ARID1A in Endometrial Cancer and the Molecular Pathways Associated With Pathogenesis and Cancer Progression. In Vivo. 2019; 33(3):659-667. PMC: 6559907. DOI: 10.21873/invivo.11524. View

4.
Zheng J, Mo J, Zhu T, Zhuo W, Yi Y, Hu S . Comprehensive elaboration of the cGAS-STING signaling axis in cancer development and immunotherapy. Mol Cancer. 2020; 19(1):133. PMC: 7450153. DOI: 10.1186/s12943-020-01250-1. View

5.
Deribe Y, Sun Y, Terranova C, Khan F, Martinez-Ledesma J, Gay J . Mutations in the SWI/SNF complex induce a targetable dependence on oxidative phosphorylation in lung cancer. Nat Med. 2018; 24(7):1047-1057. PMC: 6650267. DOI: 10.1038/s41591-018-0019-5. View